Table 2.
Colistin ELF and plasma concentrations after nebulization with different doses
| Study | Athanassa [44] (n = 20)a | Boisson [45] (n = 12)a | Bihan [46] (n = 1)b | Lu [6] (n = 16)b |
|---|---|---|---|---|
| Nebulized dose | 1 MIU | 2 MIU | 4 MIU | 5 MIU |
| Nebulizer | Vibrating mesh nebulizer, continuous delivery, optimized conditions | |||
| Colistin assay | HPLC | LC–MS/MS | LC–MS/MS | HPLC |
| VAP/VAT | VAT | VAP | VAP | VAP |
| Lung ELFmax (mg/L) | 6.73 (4.8–10.1) | 1137 | NA | NA |
| Lung ELFmin (mg/L) | 2.0 (1.0–3.8) | 9.53 | NA | NA |
| Plasma Cmax (mg/L) | 1.6 (1.5–1.9) | 0.73 | 2.9 | 2.2 ± 1.3 |
| Plasma Cmin (mg/L) | 0.3 (0.3–0.5) | 0.15 | 2.4 | 1.4 ± 0.9 |
Data are presented as mean ± SD, medians (25–75% interquartile) or maximum and minimum values
HPLC High-performance liquid chromatography, VAP ventilator-associated pneumonia; VAT ventilator-associated tracheobronchitis, ELF epithelial lining fluid, LC–MS/MS liquid chromatography–tandem mass spectrometry, Cmax maximum plasma concentration, Cmin minimum plasma concentration
a Blood sampled after the first dose; b blood sample performed at steady-state